ENvue Medical

Company Overview

Snapshot

Founded in December 2003, ENvue Medical operates with 11–50 employees and has raised a total of $24.5 million across nine funding rounds. The company went public on NASDAQ in April 2014.

Business overview

ENvue Medical develops an Enhanced Navigation platform designed to redefine clinical navigation for critical procedures such as enteral feeding and vascular access. Its technology aims to reduce complications, accelerate training, and improve efficiency in healthcare settings. The company's core products, including WoundShield, UroShield, and PainShield, serve hospitals and clinicians by making medical procedures more accurate and seamless, ultimately enhancing patient care. ENvue Medical operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, utilizing sensing, acoustics, simulation, and ultrasound technologies.

Strategic signal

In May 2026, ENvue Medical secured a three-year purchasing agreement renewal with a major Group Purchasing Organization (GPO) representing one of the largest health systems in the U.S., encompassing over 90 hospitals. This renewal signifies strong market validation for ENvue's navigation platform and its increasing adoption as a standard of care, indicating sustained revenue opportunities and strategic growth within the healthcare provider market.

Company Intelligence Q&A

What was a significant recent intellectual property development for ENvue Medical?

In May 2026, ENvue Medical added to its intellectual property portfolio by securing a USPTO Notice of Allowance for its ultrasound-enhanced cannabinoid drug delivery technology.

What recent commercial milestone did ENvue Medical achieve with a major health system?

In May 2026, ENvue Medical secured a three-year contract renewal with a 12-hospital U.S. health network, establishing its ENvue Navigation Platform as a standard of care within that system.

What was the outcome of the acquisition of Envizion Medical?

In February 2025, ENvue Medical acquired Envizion Medical. The financial terms of the acquisition were not disclosed.

What was a key product launch by NanoVibronix related to ENvue adoption?

In September 2025, NanoVibronix launched the "Oscar" Training Aid to accelerate the adoption of its ENvue platform and unlock new revenue opportunities.

What was a significant financial event for NanoVibronix in 2025?

In May 2025, NanoVibronix announced the pricing and subsequent closing of a $10 million public offering of preferred stock and warrants.